Lobaplatin
- Generic Name
- Lobaplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C9H18N2O3Pt
- CAS Number
- 135558-11-1
- Unique Ingredient Identifier
- OX5XK1JD8C
- Background
Lobaplatin has been used in trials studying the treatment of Breast Cancer, Hepatocellular Carcinoma, and Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma.
- Indication
主要用于治疗乳腺癌、小细胞肺癌及慢性粒细胞白血病。
A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 60
- Registration Number
- NCT03210389
- Locations
- 🇨🇳
Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Dose Escalation of Lobaplatin Concurrent With IMRT for the Treatment of NPC: A Phase I Clinical Trial
- Conditions
- Acute Toxic EffectsTumor Responses
- Interventions
- Device: linear accelerator
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2018-04-10
- Lead Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 17
- Registration Number
- NCT03188497
- Locations
- 🇨🇳
the Fifth Hospital Affiliated to Sun Yat-Sen University, Zhuhai, Guangdong, China
Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN
- Conditions
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2017-04-17
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Guiyang Medical University
- Target Recruit Count
- 144
- Registration Number
- NCT03117257
- Locations
- 🇨🇳
Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China
Combine TACE and RFA Versus TACE Alone for HCC With PVTT
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Ming Zhao
- Target Recruit Count
- 240
- Registration Number
- NCT02301091
- Locations
- 🇨🇳
Minimally Invasive Interventional Division, Medical Imaging Center, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China
Effectiveness and Toxicity of Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin as Second-line Treatment in Metastatic Breast Cancer
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2012-01-24
- Lead Sponsor
- Harbin Medical University
- Target Recruit Count
- 80
- Registration Number
- NCT01483300
- Locations
- 🇨🇳
Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Study of Lobaplatin，5-Fluorouracil and Leucovorin for the Treatment of Esophageal Carcinoma
- First Posted Date
- 2009-12-17
- Last Posted Date
- 2010-01-05
- Lead Sponsor
- Taian Cancer Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT01034683
- Locations
- 🇨🇳
Taian Cancer Hospital, Taian, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.